SPECIALTY QUANTITY LIMIT PROGRAM

Lorbrena (lorlatinib)

I. PROGRAM DESCRIPTION

The initial limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Lorbrena 100 mg tablets	30 per 30 days	Standard dosing: 100 mg per day Recommended dose reductions for adverse reactions: - First dose reduction: 75 mg per day - Second dose reduction: 50 mg per day
Lorbrena 25 mg tablets	90 per 30 days	

III. REFERENCE

1. Lorbrena [package insert]. New York, NY: Pfizer, Inc.; November 2018.

Specialty Quantity Limit Lorbrena 2790-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

